Table 5.

Reported bd oxidase inhibitors.

Compound	Microorganism targeted	IC50	Bacterial inhibition	Toxicity	Inhibition mechanism
Aurachin D	E. coli	18 nM (Radloff et al. 2021)	>128 μg/mL (MIC) (Dejon and Speicher 2013)	HCT-116 1 μg/mL (GI50) U-2 OS 1 μg/mL (GI50) U937 1 μg/mL (GI50) (Dejon and Speicher 2013)	Blocking of quinone binding site (Miyoshi et al. 1999; Grauel et al. 2021)
ND-01192	E..coli	0.6–1.3 μM (Kägi et al. 2023)		Mt Complex I IC50 3 μM (Kägi et al. 2023)
CK-2–63	M. tuberculosis	3 nM (Jeffreys et al. 2023)	37.8% at 5 μM (Jeffreys et al. 2023)	HepG2 IC50 85 μM 181	Blocking of quinone binding site (Jeffreys et al. 2023)